-
公开(公告)号：US11702472B2
公开(公告)日：2023-07-18
申请号：US16821674
申请日：2020-03-17
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , The U.S.A. as Represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/28 , C07K14/725 , C07K16/30 , C07K14/705 , C07K14/47 , A61K39/00 , A61K38/00 , A61K35/00
CPC分类号： C07K16/28 , C07K14/4748 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K16/30 , A61K35/00 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/03
摘要： The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
-
22.发明申请公开(公告)号：US20210324090A1
公开(公告)日：2021-10-21
申请号：US17355703
申请日：2021-06-23
发明人： Javed Khan , Sivasubramanian Baskar , Rimas J. Orentas , Dimiter S. Dimitrov , Zhongyu Zhu , Tai Chi Cheuk
IPC分类号： C07K16/28 , A61K47/68 , A61K47/69 , A61P35/00 , A61K39/395
摘要： Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
-
公开(公告)号：US11103533B2
公开(公告)日：2021-08-31
申请号：US16698186
申请日：2019-11-27
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
摘要： Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US11045497B2
公开(公告)日：2021-06-29
申请号：US16698186
申请日：2019-11-27
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
摘要： Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20200155661A1
公开(公告)日：2020-05-21
申请号：US16773379
申请日：2020-01-27
申请人： LentigenTechnology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K39/00 , A61P35/00 , C07K14/725 , C07K14/705 , C07K16/28
摘要： Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
-
公开(公告)号：US10550179B2
公开(公告)日：2020-02-04
申请号：US16252158
申请日：2019-01-18
申请人： Lentigen Technology Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C12N15/62 , C12N15/63 , C12N15/09 , C12N15/10 , C12N5/0783 , C07K16/28 , C07K16/30 , C07K14/705 , C07K14/725 , A61K35/17 , A61K39/395 , C07K16/18 , A61P35/02 , A61P35/00
摘要： Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20180134800A1
公开(公告)日：2018-05-17
申请号：US15843256
申请日：2017-12-15
发明人： Mitchell Ho , Mingqian Feng , Dimiter S. Dimitrov , Wei Gao
IPC分类号： C07K16/30 , A61K39/395 , G01N33/68 , C07K14/21 , G01N33/574 , C07K16/28 , A61K39/00
CPC分类号： C07K16/3076 , A61K39/39558 , A61K47/6803 , A61K47/6813 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K14/21 , C07K16/28 , C07K16/303 , C07K16/3092 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00 , C07K2319/33 , C07K2319/55 , G01N33/57438 , G01N33/57492 , G01N33/6893 , G01N2333/705 , G01N2400/40
摘要： Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.
-
公开(公告)号：US20240067724A1
公开(公告)日：2024-02-29
申请号：US18330587
申请日：2023-06-07
申请人： LENTIGEN TECHNOLOGY, INC. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/28 , A61K35/17 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C12N5/0783
CPC分类号： C07K16/2803 , A61K35/17 , A61K39/0011 , A61K39/001112 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70596 , C12N5/0636 , A61K2035/124 , C07K2317/73 , C07K2319/02 , C07K2319/03 , C07K2319/035
摘要： Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20230312706A1
公开(公告)日：2023-10-05
申请号：US18318588
申请日：2023-05-16
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , The U.S.A. as Represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/28 , C07K14/725 , C07K16/30 , C07K14/705 , C07K14/47
CPC分类号： C07K16/28 , C07K14/7051 , C07K16/30 , C07K14/705 , C07K14/70517 , C07K14/70521 , C07K14/4748 , A61K2039/505
摘要： The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
-
公开(公告)号：US20220389094A1
公开(公告)日：2022-12-08
申请号：US17820785
申请日：2022-08-18
申请人： Lentigen Technology, Inc. , The U.S.A. as represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/28 , C12N15/62 , C12N15/113 , A61P35/00 , A61K38/17 , C07K14/15 , C07K14/705 , C07K14/735 , C07K14/73 , C07K14/725
摘要： Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.032 秒)
